Retatrutide
Also known as: LY3437943
Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. Its mechanism combines appetite suppression with incretin and glucagon-axis metabolic effects, so ProtoComp should frame all guidance as investigational and monitor heart rate, glucose, nausea, and energy availability.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England journal of medicine · 2023 · PMID 37366315
Investigational triple agonist (GLP-1/GIP/glucagon). Phase 3 trials ongoing. Dose range reflects published trial protocols, not FDA-approved labeling.
No cycle range recorded.
Limited published titration guidance outside trial protocols.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- • History of pancreatitis
Common side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Decreased appetite
- • Fatigue (higher than Semaglutide in trials)
Serious risks
- • Long-term safety not established — investigational
- • Pancreatitis risk class effect
Drug interactions
- • Delays gastric emptying
Requires monitoring
- • HbA1c
- • Weight
- • Kidney function
Pregnancy / breastfeeding
Contraindicated — investigational
- Not FDA approved — trial-stage compound with unknown long-term safety profile
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.